Cholesterol Lowering Drugs to Go Over the Counter

Analysts believe that with Britain on the verge of clearing over-the-counter sales of a top-selling cholesterol drug, the United States will likely be the next big market as regulators warm to the idea of a switch. The FDA in 2000 rejected the initial bid to move Merck's Mevacor and Bristol-Myers Squibb's Pravachol to nonprescription status because of safety concerns. But the agency has taken a more positive view of prescription-to-OTC switches in recent years, boosting chances for a switch...

Read the Full Article for Free!

You can unsubscribe at any time and I guarantee the privacy of your email. View our privacy policy

Subscribe for FREE to the #1 Natural Health Newsletter or Login for Instant Access

Unlock censored health information that Google doesn't want you to read

Keep your privacy secure — we are one of the few websites that have banned all Google and Facebook scripts to help stop their surveillance capitalism

Get access to all of Dr. Mercola's health articles, E-books and special reports